Thc Therapeutics Stock Performance
| THCT Stock | USD 0.0005 0 89.13% |
THC Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The entity owns a Beta (Systematic Risk) of -19.81, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning THC Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, THC Therapeutics is expected to outperform it. Use THC Therapeutics coefficient of variation, total risk alpha, as well as the relationship between the Total Risk Alpha and day median price , to analyze future returns on THC Therapeutics.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in THC Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental indicators, THC Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 43.2 K |
THC |
THC Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.30 in THC Therapeutics on August 31, 2024 and sell it today you would lose (0.25) from holding THC Therapeutics or give up 83.33% of portfolio value over 90 days. THC Therapeutics is currently generating 10.3401% in daily expected returns and assumes 102.3395% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than THC, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
THC Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for THC Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as THC Therapeutics, and traders can use it to determine the average amount a THC Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.101
| Best Portfolio | Best Equity | THCT | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 102.34 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average THC Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of THC Therapeutics by adding it to a well-diversified portfolio.
THC Therapeutics Fundamentals Growth
THC Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of THC Therapeutics, and THC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on THC Pink Sheet performance.
| Return On Asset | -5.57 | |||
| Current Valuation | 1.57 M | |||
| Shares Outstanding | 34.15 M | |||
| Price To Earning | 1.25 X | |||
| Price To Book | 46.07 X | |||
| EBITDA | (1.06 M) | |||
| Cash And Equivalents | 3.82 K | |||
| Total Debt | 925.89 K | |||
| Debt To Equity | 18.70 % | |||
| Book Value Per Share | (0.15) X | |||
| Cash Flow From Operations | (388.48 K) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 480.07 K | |||
About THC Therapeutics Performance
Assessing THC Therapeutics' fundamental ratios provides investors with valuable insights into THC Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the THC Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada. Thc Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about THC Therapeutics performance evaluation
Checking the ongoing alerts about THC Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for THC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| THC Therapeutics is way too risky over 90 days horizon | |
| THC Therapeutics has some characteristics of a very speculative penny stock | |
| THC Therapeutics appears to be risky and price may revert if volatility continues | |
| THC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| THC Therapeutics currently holds 925.89 K in liabilities with Debt to Equity (D/E) ratio of 18.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. THC Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist THC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, THC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (1.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| THC Therapeutics currently holds about 3.82 K in cash with (388.48 K) of positive cash flow from operations. | |
| Roughly 31.0% of THC Therapeutics outstanding shares are owned by corporate insiders |
- Analyzing THC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether THC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining THC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating THC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of THC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of THC Therapeutics' pink sheet. These opinions can provide insight into THC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.